Sexton Kerry, Lennon Diana, Oster Philipp, Crengle Sue, Martin Diana, Mulholland Kim, Percival Teuila, Reid Stewart, Stewart Joanna, O'Hallahan Jane
Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand.
N Z Med J. 2004 Aug 20;117(1200):U1015.
The New Zealand Meningococcal Vaccine Strategy aims to end the devastating 14-year epidemic of B:4:P1.7b,4 group B meningococcal disease in New Zealand through a mass immunisation programme to all under 20 year olds using a tailor-made vaccine (MeNZB). This paper describes the scientific rationale, development, and key components of the New Zealand Meningococcal Vaccine Strategy. A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy.
新西兰脑膜炎球菌疫苗战略旨在通过一项针对所有20岁以下人群的大规模免疫计划，使用特制疫苗（MeNZB），终结在新西兰肆虐了14年的B:4:P1.7b,4型B群脑膜炎球菌病疫情。本文描述了新西兰脑膜炎球菌疫苗战略的科学依据、研发过程及关键组成部分。文中还总结了现有B群脑膜炎球菌外膜囊泡疫苗的有效性和安全性数据，因为这些数据对该战略至关重要。
